Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.14 USD | +1.56% | +2.70% | +22.68% |
04-02 | North American Morning Briefing : Stocks Seen -2- | DJ |
03-28 | Talis Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | 4.81M 6.58M | Sales 2023 | 2.13M 2.92M | Capitalization | 13.57M 18.55M |
---|---|---|---|---|---|
Net income 2022 | -113M -154M | Net income 2023 | -62M -84.75M | EV / Sales 2022 | -17.6 x |
Net cash position 2022 | 96.61M 132M | Net cash position 2023 | 57.06M 78M | EV / Sales 2023 | -20.4 x |
P/E ratio 2022 |
-0.11
x | P/E ratio 2023 |
-0.22
x | Employees | 99 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.69% |
Latest transcript on Talis Biomedical Corporation
1 day | +1.56% | ||
1 week | +2.70% | ||
Current month | +4.46% | ||
1 month | +1.56% | ||
3 months | +16.14% | ||
6 months | +97.46% | ||
Current year | +22.68% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Kelley
CEO | Chief Executive Officer | 52 | 20-08-31 |
Director of Finance/CFO | 51 | 21-12-31 | |
Kim Popovits
BRD | Director/Board Member | 65 | 20-07-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 56 | 16-02-29 |
Randal Scott
BRD | Director/Board Member | 66 | 13-12-31 |
Kim Popovits
BRD | Director/Board Member | 65 | 20-07-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 9.14 | +1.56% | 4,549 |
24-04-25 | 9 | -2.18% | 3,730 |
24-04-24 | 9.2 | +2.11% | 3,352 |
24-04-23 | 9.01 | +0.11% | 8,738 |
24-04-22 | 9 | +1.12% | 9,727 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+22.68% | 16.65M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TLIS Stock